Literature DB >> 20501506

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

C Ferté1, B Besse2, E Dansin3, F Parent4, M-P Buisine5, M-C Copin6, N Penel3, J-C Soria7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20501506     DOI： 10.1093/annonc/mdq153

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

1.  Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.

Authors:  Matthew A Smith; Richard Hall; Kate Fisher; Scott M Haake; Farah Khalil; Matthew B Schabath; Vincent Vuaroqueaux; Heinz-Herbert Fiebig; Soner Altiok; Yian Ann Chen; Eric B Haura
Journal:  Sci Signal       Date:  2015-01-13       Impact factor: 8.192

2.  Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.

Authors:  Cesare Gridelli; Filippo de Marinis; Andrea Ardizzoni; Silvia Novello; Gabriella Fontanini; Federico Cappuzzo; Francesco Grossi; Antonio Santo; Diego Cortinovis; Adolfo Favaretto; Vito Lorusso; Domenico Galetta; Salvatore Siena; Anna Bettini; Monica Iurlaro; Alberto Caprioli
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-06       Impact factor: 4.553

3.  KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments.

Authors:  Barbara L Parsons; Meagan B Myers
Journal:  Per Med       Date:  2013-03       Impact factor: 2.512

Review 4.  The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Kristine Raaby Jakobsen; Christina Demuth; Boe Sandahl Sorensen; Anders Lade Nielsen
Journal:  Transl Lung Cancer Res       Date:  2016-04

Review 5.  Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.

Authors:  Christopher Delaney; Samuel Frank; R Stephanie Huang
Journal:  Chin J Cancer       Date:  2015-04-08

6.  Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.

Authors:  Anna K Brady; Jonathan D McNeill; Brendan Judy; Joshua Bauml; Tracey L Evans; Roger B Cohen; Corey Langer; Anil Vachani; Charu Aggarwal
Journal:  Oncotarget       Date:  2015-10-06

7.  Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report.

Authors:  Dragana Jovanovic; Ruza Stevic; Marta Velinovic; Milica Kontic; Dragana Maric; Jelena Spasic; Davorin Radosavljevic
Journal:  Onco Targets Ther       Date:  2017-09-06       Impact factor: 4.147

8.  KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Authors:  Mirko Marabese; Monica Ganzinelli; Marina C Garassino; Frances A Shepherd; Sheila Piva; Elisa Caiola; Marianna Macerelli; Anna Bettini; Calogero Lauricella; Irene Floriani; Gabriella Farina; Flavia Longo; Lucia Bonomi; M Agnese Fabbri; Silvio Veronese; Silvia Marsoni; Massimo Broggini; Eliana Rulli
Journal:  Oncotarget       Date:  2015-10-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.